Previous studies showed that homocysteine, a thromboatherogenic and atherogenic agent, inhibits an endothelial thrombomodulin-protein C anticoagulant pathway. We examined whether homocysteine might affect another endothelial anticoagulant mechanism; i.e., heparin-like glycosamino-glycan-antithrombin III interactions. Incubations of porcine aortic endothelial cell cultures with homocysteine reduced the amount of antithrombin III bound to the cell surface in a dose-and timedependent fashion. The inhibitory effect was observed at a homocysteine concentration as low as 0.1 mM, and the maximal suppression occurred at 1 mM of homocysteine after 24 h. In contrast with a marked reduction in the maximal antithrombin III binding capacity (-30% of control), the radioactivity of I35Slsulfate incorporated into heparan sulfate on the cell surface was minimally (< 15%) reduced. The cells remained viable after homocysteine treatment. Although neither net negative charge nor proportion in total glycosaminoglycans of cell surface heparan sulfate was altered by homocysteine treatment, a substantial reduction in antithrombin III binding capacity of heparan sulfate isolated from homocysteine-treated endothelial cells was found using both affinity chromatography and dot blot assay techniques. The antithrombin III binding activity of endothelial cells decreased after preincubation with 1 mM homocysteine, cysteine, or 2-mercaptoethanol; no reduction in binding activity was observed after preincubation with the same concentration of methionine, alanine, or valine. This sulfhydryl effect may be caused by generation of hydrogen peroxide, as incubation of catalase, but not superoxide dismutase, with homocysteine-treated endothelial cells prevented this reduction, whereas copper augmented the inhibitory effects of the metabolite. Thus, our data suggest that the inhibited expression of anticoagulant heparan sulfate may contribute to the thrombogenic property resulting from the homocysteine-induced endothelial cell perturbation, mediated by generation of hydrogen peroxide through alteration of the redox potential. (J. Clin.
Introduction
Previous studies showed that homocysteine, a thromboatherogenic and atherogenic agent, inhibits an endothelial thrombomodulin-protein C anticoagulant pathway. We examined whether homocysteine might affect another endothelial anticoagulant mechanism; i.e., heparin-like glycosamino-glycan-antithrombin III interactions. Incubations of porcine aortic endothelial cell cultures with homocysteine reduced the amount of antithrombin III bound to the cell surface in a dose-and timedependent fashion. The inhibitory effect was observed at a homocysteine concentration as low as 0.1 mM, and the maximal suppression occurred at 1 mM of homocysteine after 24 h. In contrast with a marked reduction in the maximal antithrombin III binding capacity (-30% of control), the radioactivity of I35Slsulfate incorporated into heparan sulfate on the cell surface was minimally (< 15%) reduced. The cells remained viable after homocysteine treatment. Although neither net negative charge nor proportion in total glycosaminoglycans of cell surface heparan sulfate was altered by homocysteine treatment, a substantial reduction in antithrombin III binding capacity of heparan sulfate isolated from homocysteine-treated endothelial cells was found using both affinity chromatography and dot blot assay techniques. The antithrombin III binding activity of endothelial cells decreased after preincubation with 1 mM homocysteine, cysteine, or 2-mercaptoethanol; no reduction in binding activity was observed after preincubation with the same concentration of methionine, alanine, or valine. This sulfhydryl effect may be caused by generation of hydrogen peroxide, as incubation of catalase, but not superoxide dismutase, with homocysteine-treated endothelial cells prevented this reduction, whereas copper augmented the inhibitory effects of the metabolite. Thus, our data suggest that the inhibited expression of anticoagulant heparan sulfate may contribute to the thrombogenic property resulting from the homocysteine-induced endothelial cell perturbation, mediated by generation of hydrogen peroxide through alteration of the redox potential. (J. Clin. Invest. 1993. 92:1381-1386.) Key words: arteriosclerosisthrombosis * antithrombin III * proteoglycan * hydrogen peroxide Endothelial cells possess several antithrombotic mechanisms, including thrombomodulin-protein C and heparin-like glycosaminoglycan-antithrombin III anticoagulant pathways (1) . Little is known, however, how these endothelial cell functions are regulated, and whether modulations of these functions could lead to thrombosis and/or vascular injury. The cytokines, potent immunologic and inflammatory mediators, have been shown to suppress anticoagulant activity through decreased cell surface thrombomodulin (2, 3) and heparin-like compounds on endothelial cells (4) . These mechanisms may contribute to the thrombus formation and vasculopathy associated with inflammatory responses (5) .
Homocysteinemia caused by homozygous cystathionine B-synthase deficiency is associated with an increased incidence of vascular thrombosis and development of arteriosclerosis (6) . Furthermore, elevated plasma homocysteine levels have been reported to be an independent risk factor for vascular disease (7) (8) (9) (10) . The administration of homocysteine caused vascular injury and thrombosis in animals ( 11) . The mechanisms by which homocysteinemia leads to thrombosis and arteriosclerosis has not been completely defined yet. Recent studies using cell culture systems have shown that homocysteine enhances endothelial cell-associated Factor V activity ( 12) , and inhibits both thrombomodulin surface expression and protein C activation (13) (14) (15) . Thus, endothelial cell coagulant properties were shown to be regulated by atherogenic stimuli. To our knowledge, however, no studies have yet reported the involvement ofanother important endothelial anticoagulant pathway; i.e., endothelial cell heparin-like glycosaminoglycans-antithrombin III anticoagulant mechanism, in this unique model of thrombosis and arteriosclerosis.
The present study was Endothelial cell cultures. Porcine aortic endothelial cells were cultured in gelatin-precoated 35-mm Petri dishes containing RPMI 1640 medium, supplemented with 10% fetal calf serum and antibiotics as previously described (16) (17) (18) . Cells in the third to fourth passage were used throughout the experiment. For treatment ofcells with homocysteine and other agents, when cells were grown close to confluence, the medium was replaced with fresh culture medium containing 10% fetal calf serum. Incubations were further continued for the indicated periods of time in the presence or absence of various concentrations of these compounds. Radiochromium release assay was performed as described previously ( 19)..
Antithrombin III binding to endothelial cells. Antithrombin III was labeled with 125I by using Iodogen, as previously described (18 (16) with slight modifications. Briefly, the washed cell layers were trypsinized and resultant cell suspensions were centrifuged to obtain a supernatant ("cell surface fractions"). Trypsin can effectively remove glycosaminoglycans from the cell surface and from the solubilized matrix ( 16) . 35S-labeled glycosaminoglycans were precipitated by 85% ethanol containing 1.3% potassium acetate before or after treatments with 0.5 IU/ml of chondroitin ABC lyase, after proteolytic digestion with pronase. Heparan sulfate was determined as chondroitin ABC lyase-resistant glycosaminoglycans. After incubations at -20°C for 12 h, the precipitate was collected by centrifugation at 10,000 g for 30 min. These were dissolved in 0.1 ml of water, and their radioactivities were measured by liquid scintillation counting. Protein contents in the cells were measured according to Lowry et al. (20) .
The nature of radiolabeled glycosaminoglycans was analyzed by anion exchange high performance liquid chromatography on Mono Q, and that of heparan sulfate by antithrombin III affinity chromatography on Affi-Gel as previously described ( 18) .
Detection ofheparan sulfate with high-affinityfor antithrombin III by dot blot assay. Cell surface heparan sulfate with high affinity for antithrombin III was also quantitated by their ability to bind radiolabeled antithrombin III, as judged by a nitrocellulose dot-blot assay described by Kojima et al. (21). Heparan sulfate from control and homocysteine-treated cells with an equal amount of 35S radioactivity was diluted in phosphate buffered saline and transferred onto nitrocellulose membranes placed in a dot-blot apparatus. The blotted membranes were then incubated with phosphate buffered saline containing 5% nonfat milk at 220C for 1 h. [ '25I ] Antithrombin III was added at a concentration of 1 X 106 cpm/ ml, and an additional incubation of 1 h was carried out at 220C. After washes, the membrane was incubated with phosphate buffered saline containing 0.8 M NaCl for 1 h, and was then washed with phosphate buffered saline containing 5 mM MgCI2, 5 mM CaCl2, and 5 jig/ml of bovine serum albumin, dried, and quantitated by autoradiography.
Results
Effects ofhomocysteine on endothelial cell viability. Previous studies ( 19, 22) showed that homocysteine-induced cytotoxicity occurred in proportion to the incubation time and the concentrations of both homocysteine and serum in the culture medium. The susceptibility to homocysteine also varied, depending on differences in species and vascular sites from which endothelial cells were derived. The conditions used in the present study; i.e., incubations of porcine aortic endothelial cells with 0.1-1 mM homocysteine in the presence of 10% fetal calf serum for < 24 h, did not produce cell detachment, loss of viability determined by trypan blue dye exclusion, or any change in microscopic appearances or protein contents of the cells. In addition, no significant specific release of 5"Cr was (Fig. 3) . The strated two major peaks (Fig. 4) . After chondroitin ABC lyase treatment, only an earlier larger peak was detectable, indicating that it represented heparan sulfate. Neither elution positions nor proportion of heparan sulfate (74±4 vs 74±8% of total 35S-glycosaminoglycans for control and homocysteine-treated endothelial cells respectively, mean±SEM ofthree separate experiments) was affected by homocysteine treatment.
The results of fractionation of 35S-labeled heparan sulfate by affinity chromatography on antithrombin-Affi-Gel are shown in Fig. 5 . A portion ofthe high affinity material that was eluted by 0.8-2 M NaCl was 61% less in homocysteine-treated cells than in control cells. The dot-blot assay produced consistent results (Fig. 6) . The densitometry showed that heparan sulfate from homocysteine-treated cells revealed less [125I]_ antithrombin III binding activity than that from control cells (42±3% of control, mean±SEM of three determinations).
Mechanisms offindings. The specificity of reduced antithrombin III binding was examined using additional sulfhydryl agents. The antithrombin III binding activity decreased after preincubation with 1 mM homocysteine, cysteine, or 2-mercaptoethanol, all of which contain free thiol groups (Fig.  7) . No reduction in binding activity was observed after preincubation with the same concentration of methionine, alanine (or valine, not shown). Thus, the inhibition of antithrombin III binding to endothelial cells may be mediated by a sulfhydryl-dependent mechanism.
Further evidence for sulfhydryl-dependent reaction was provided by the addition of the free radical scavenger, catalase ( 1,000 U/ml) or superoxide dismutase (200 U/ml). Coincubation with catalase completely prevented the inhibition of [1251 ] antithrombin III binding to endothelial cells by homocysteine (Fig. 8) Previous studies showed that homocysteine decreased cell surface thrombomodulin expression and protein C activation, suggesting that the perturbation ofthe vascular endothelial cell protein C mechanism by homocysteine may contribute to the thrombotic tendency seen in patients with elevated blood levels of this metabolite (13) (14) (15) . In the present study, we showed that homocysteine-treated endothelial cells largely lost an-100- (21, 23) . This interaction between endothelial heparin-like compounds and the protease inhibitor is believed to contribute to the anticoagulant activity of the endothelial cells ( 1, 24) . Thus, we demonstrated for the first time that homocysteine specifically inhibits the expression of endothelial anticoagulant heparin-like compounds, thereby perturbing an endothelial anticoagulant mechanism mediated by the interaction with antithrombin III.
The mechanism ofthe synthesis and expression ofanticoagulant heparan sulfate in endothelial cells is not well known. It requires the production of a core protein; assembly ofa linkage region of four monosaccaride units; generation of a precursor oligosaccharide chain; and subsequent polymer-modification reactions including deacetylation of N-acetylglucosamine residues, N-sulfation of the resulting free amino groups, conversion of D-glucuronic acid to L-iduronic acid units by epimerization at C-5, O-sulfation at C-2 of iduronic acid units, and 0-sulfation at C-6 of glucosamine units. The final step of this complex remodeling process is thought to be the glucosamine-3-0-sulfotransferase reaction resulting in the generation of a region ofa unique sequence ofsulfated and nonsulfated uronic acid and glucosamine residues, which are required to complex with the protease inhibitor (25, 26 ). Homocysteine appears to perturb this biosynthetic pathway in rather a specific way, and diminish cell-surface expression of anticoagulant heparan sulfate with high affinity for antithrombin III, without gross alterations of overall cellular glycosaminoglycan biosynthesis. The mechanism by which cells treated with the metabolite are defective in the synthesis and/or subsequent expression on the cell surface ofheparan sulfate with the unique monosaccharide sequence required for the binding of antithrombin III remains to be determined. The synthesis of specific core proteins for anticoagulantly active heparan sulfate (21 ), if any, or the multimolecular arrays ofbiosynthetic enzymes that carry out posttranslational modifications of the oligosaccaride chains within the Golgi complex might be perturbed by homocysteine. The latter concept is in accord with the recent study ( 14) however, that the inhibition of antithrombin III binding by homocysteine occurred without apparent "cellular injury", and that this effect was evident only after no less than 6 h of incubation in the present study, suggesting that hydrogen peroxide generation primarily may have affected biosynthetic processes of anticoagulant heparan sulfate in endothelial cells, but not directly "injured" those already present on the cell surface.
On the other hand, it has been shown that homocysteine-induced suppression of protein C activation by endothelial cells is more rapid; i.e., > 50% reduction within 0.5-3 h (13, 15) , and that sulfhydryl groups may (14) or may not (13, 15) be required for this effect. The role of hydrogen peroxide was not evident in one of those studies ( 13) . Instead, homocysteine may directly inhibit the thrombomodulin cofactor activity by reducing the disulfide-bond structures of the protein, with an increase in thrombomodulin mRNA and thrombomodulin protein synthesis as a compensatory mechanism (13, 15) . Thus, homocysteine might inhibit two major anticoagulant pathways in endothelial cells by different mechanisms. The inhibitory effect ofhomocysteine occurred at an -10-fold less concentration of the metabolite in the present study than that used in the previous experiments (13-15) (0.1-1 mM vs 1-10 mM, respectively). Plasma concentrations of free homocysteine present in homocystinuric patients are reported to be less than 1 mM ( 12), while levels of homocysteine found in plasma of patients with premature vascular disease are considerably lower than those in homozygous homocysteinemic patients; e.g., 10-30 ,M of homocysteine (7) (8) (9) (10) . Our data showing the inhibited expression of antithrombin III-mediated anticoagulant system in endothelial cells by homocysteine concentration as low as 0.1 mM, or even at as lower concentration as 10 ,AM in some conditions affecting redox potential; e.g., in the presence ofcopper ion, may be pathophysiologically relevant, at least in certain clinical situations. Furthermore, the inhibited expression of anticoagulant heparan sulfate may be a highly sensitive marker of "endothelial cell perturbation" subsequent to alteration of the redox potential.
